Protocol SummaryBack To Search Instructions
Protocol No.2083GCCCPrincipal InvestigatorMehra, Ranee
PhasePhase II
Title2083GCCC: Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma
DescriptionA Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
TreatmentExperimental: Goserelin Acetate + Pembrolizumab Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV Interventions: Drug: Goserelin Acetate Drug: Pembrolizumab
Key EligibilityFor more information on eligibility visit and search NCT03942653
Applicable Disease SitesH&N
Treatment TypeTreatment
ContactRehan Khan Phone:
Back to Protocol Listing